



TRANSMITTAL FORM

(To be used for all correspondence
after initial filing)

Application Number	10/627,586
Filing Date	July 25, 2003
First Named Inventor	Khalid Mekouar
Art Unit	
Examiner Name	
Attorney Docket No.	660081.442

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> CD(s), Number of CD(s) _____
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Request for Corrected Filing Receipt	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Amendment/Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Appeal Communication to Group (Proprietary Information)
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Declaration	<input checked="" type="checkbox"/> Return Receipt Postcard
<input checked="" type="checkbox"/> Information Disclosure Statement; Form PTO-1449 (2 Sheets)	<input type="checkbox"/> Statement under 37 CFR 3.73(b)	<input type="checkbox"/> Additional Enclosure(s) (please identify below):
<input checked="" type="checkbox"/> 18 Cited References	<input type="checkbox"/> Terminal Disclaimer	_____
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request for Refund	_____
<input type="checkbox"/> Response to Missing Parts under 37 C.F.R. 1.52 or 1.53		_____
<input type="checkbox"/> Response to Missing Parts/Incomplete Application		_____

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Individual Name	Jeffrey C. Pepe, Ph.D. Reg. No. 46,985	Customer Number 00500
Signature		
Date	October 31, 2003	

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Lawrence Teague	
Signature		Date: October 31, 2003

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. 429000



PATENT

I hereby certify that on the date specified below, this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

October 31, 2003

Date

Lawrence Teague
Lawrence Teague

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Khalid Mekouar et al.
Application No. : 10/627,586
Filed : July 25, 2003
For : ANTI-VIRAL 7-DEAZA D-NUCLEOSIDES AND USES THEREOF

Docket No. : 660081.442

Date : October 31, 2003

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the U.S. Patent and Trademark Office the references set forth on the attached form PTO-1449 (copies of the cited references are enclosed). Applicants also wish to disclose and have officially considered the following co-pending application by the same assignee, listed on page 2 (reference BL) of the attached forms PTO-1449:

Application No.	Title	Filed
10/326,573	ANTI-VIRAL 7-DEAZA L-NUCLEOSIDES	December 20, 2002

As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such


reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Applicants believe this Information Disclosure Statement has been timely filed, however, the Director is authorized to charge any fee due by way of this Information Disclosure Statement to our Deposit Account No. 19-1090.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC



Jeffrey C. Pepe, Ph.D.
Registration No. 46,985

JCP:ljt

Enclosures:

Postcard
Transmittal Form
Form PTO-1449
Cited References (18)

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

428999


FORM PTO-1449
(REV. 7-80)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

660081.442

APPLICATION NO.

10/627,586

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Khalid Mekouar et al.

FILING DATE

July 25, 2003

GROUP ART UNIT

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	4,328,336	05/04/82	Robins et al.	536	28	
	AB	5,041,542	08/20/91	Robins et al.	536	24	
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AI	WO 98/16184	04/23/98	WIPO		
	AJ					
	AK					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AL	Aguesse-Germon, S. et al., "Inhibitory Effect of 2'-Fluoro-5-Methyl-β-L-Arabinofuranosyl-Uracil on Duck Hepatitis B Virus Replication," <i>Antimicrobial Agents and Chemotherapy</i> 42(2): 369-376, February 1998.
	AM	Bonnet, P. et al., "Modulation of Leukocyte Genetic Expression by Novel Purine Nucleoside Analogues. A New Approach to Antitumor and Antiviral Agents," <i>Journal of Medicinal Chemistry</i> 36(6): 635-653, March 1993.
	AN	Girgis, N. et al., "Direct C-Glycosylation of Guanine Analogues: The Synthesis and Antiviral Activity of Certain 7- and 9-Deazaguanine C-Nucleosides," <i>Journal of Medicinal Chemistry</i> 33: 2750-2755, 1990.
	AO	Jaffray, C.E. et al., "Blood-borne Viral Diseases and the Surgeon," <i>Curr. Probl. Surg.</i> 40: 195-251, April 2003.
	AP	Korba, B et al., "A cell culture assay for compounds which inhibit hepatitis B virus replication," <i>Antiviral Research</i> 15: 217-228, 1991.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

660081.442

APPLICATION NO.

10/627,586

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Khalid Mekouar et al.

FILING DATE

July 25, 2003

GROUP ART UNIT

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
BA						

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO
BB			

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

BC	Korba, B. et al., "Use of a standardized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication," <i>Antiviral Research</i> 19: 55-70, 1992.
BD	Lin, T. et al., "8-Substituted Guanosine and 2'-Deoxyguanosine Derivatives as Potential Inducers of the Differentiation of Friend Erythroleukemia Cells," <i>Journal of Medicinal Chemistry</i> 28: 1194-1198, 1985.
BE	Michael, M. et al., "Alkylpurines as Immunopotentiating Agents. Synthesis and Antiviral Activity of Certain Alkylguanines," <i>Journal of Medicinal Chemistry</i> 36: 3431-3446, 1993.
BF	Reitz, A. et al., "Small-Molecule Immunostimulants. Synthesis and Activity of 7,8-Disubstituted Guanosines and Structurally Related Compounds," <i>Journal of Medicinal Chemistry</i> 37: 3561-3578, 1994.
BG	Revankar, G. et al., "Synthesis and Antiviral/Antitumor Activities of Certain 3-Deazaguanine Nucleosides and Nucleotides," <i>Journal of Medicinal Chemistry</i> 27(11): 1390-1396, 1984.
BH	Tennant, B. et al., "The Woodchuck Model of Hepatitis B Virus Infection," <i>ILAR Journal</i> 42(2): 89-102, 2001.
BI	Weigle, W., "Factors and Events in the Activation, Proliferation, and Differentiation of B Cells," <i>Critical Reviews in Immunology</i> 7(4): 285-324, 1987.
BJ	Younossi, Z., "Viral hepatitis guide for practicing physicians," <i>Cleveland Clinic Journal of Medicine</i> 67(Suppl. 1): SI6-SI45, 2000.
BK	Zuckerman, A.J., "Screening of antiviral drugs for hepadna virus infection in Pekin ducks: a review," <i>Journal of Virological Methods</i> 17: 119-126, 1987.
BL	Deziel et al., "Anti-Viral 7-Deaza L-nucleosides," U.S. Patent Application No. 10/326,573, filed December 20, 2002.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).